 |
Photo: Yonhap News Agency |
[Alpha Biz= Kim Jisun] SEOUL, August 7, 2025 — LG Chem announced today that it will sell its Aesthetics Business Unit, under the Life Sciences Division, to South Korean private equity firm VIG Partners for approximately KRW 200 billion (USD 150 million). The move is part of LG Chem’s portfolio restructuring to sharpen its core competitiveness.
The divestment represents roughly 0.42% of LG Chem’s total equity of KRW 47.9955 trillion as of the end of 2024.
LG Chem’s Life Sciences Division comprises three main business areas:
Primary Care (Prescription drugs)
Specialty Care (growth hormones, vaccines, osteoarthritis injectables, etc.)
Aesthetics (dermal fillers and fat-dissolving injections)
The Aesthetics Business Unit markets products such as the Yvoire (HA filler) and Bellacollin (lipolysis injection). In 2024, the unit recorded sales of approximately KRW 100 billion, with an EBITDA of KRW 25 billion.
As part of the deal, LG Chem will also transfer ownership of its China-based aesthetics subsidiary, which was initially launched in 2021 through a joint venture with Chinese pharmaceutical firm Hangzhou GenSci. Earlier this year, LG Chem acquired full ownership of the JV, taking over all operations related to Yvoire fillers in the Chinese market.
The sale process has been managed by HSBC Securities, which was appointed as LG Chem’s financial advisor earlier this year.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
